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creativecommons.org/licenses/by-nc-nd/Abstract Aim: Intensive treatment regimens have contributed to a marked increase in child-
hood cancer survival rates. Death due to treatment-related adverse effects becomes an increas-
ingly important area to further improve overall survival. In this study, we examined 5-year
survival in children with cancer to identify risk factors for treatment-related mortality (TRM).
Methods: All children (aged <18 years at diagnosis) diagnosed with cancer in 2 Dutch univer-
sity hospitals between 2003 and 2013 were included, survival status was determined and causes
of death were analysed. Various demographic and treatment factors were evaluated, for which
a multivariable competing risks analysis was performed.
Results: A total of 1764 patients were included; overall 5-year survival was 78.6%. Of all 378
deaths, 81 (21.4%) were treatment-related, with infection being responsible for more than half
of these deaths. Forty percent of TRM occurred in the first three months after initial diag-
nosis. Factors associated with TRM in the multivariable competing risks analysis were diag-
nosis of a haematological malignancy, age at diagnosis <1 year and receipt of allogeneic
haematopoietic stem cell transplantation. In children suffering from haematological malig-
nancies, TRM accounted for 56.3% of 103 deaths.1, 9700, RB Groningen, University of Groningen, University Medical Center Groningen, Groningen, the
l (E.A.H. Loeffen).
contributed equally to this work.
lished by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://
4.0/).
E.A.H. Loeffen et al. / European Journal of Cancer 121 (2019) 113e122114Conclusion: Over one in five deaths in children with cancer death was related to treatment,
mostly due to infection. In children suffering from a haematological malignancy, more chil-
dren died due to their treatment than due to progression of their disease. To further increase
overall survival, clinical and research focus should be placed on lowering TRM rates without
compromising anti-tumour efficacy. The findings presented in this study might help identifying
areas for improvement.
ª 2019 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Cure rates of children with cancer have increased greatly
in the past decades, largely because of more intensive,
multimodal treatment regimens [1]. These treatment
regimens are however associated with several adverse
effects, such as pain, febrile neutropenia and nausea.
These diminish quality of life and can have serious
treatment implications, such as delay or reduction of
anti-cancer treatment. In addition, some children with
cancer die as a result of these intensive treatments. As
the cure rates keep improving and fewer children die of
cancer, treatment-related mortality (TRM) becomes an
increasingly important area to further improve overall
survival [2].
Various specific causes for TRM exist. A well-
known cause is infection, which is the cause of death
in one in 40 children with acute lymphoblastic
leukaemia (ALL) [3]. The list of other causes of TRM
is long, with haemorrhage, graft-versus-host disease
and encephalopathy, amongst others [4]. Discrimi-
nating TRM and progressive disease (PD) death is not
always straightforward. One might say all deaths are
due to cancer as the child would not have undergone
cancer treatment without the disease. It is also
dependent on the specific type of cancer and accom-
panying intensity of treatment. In addition, there are
causes that fit neither TRM nor PD death, for
instance, an accident or death due to underlying co-
morbidity.
In 2015, the International Pediatric Oncology Mor-
tality Classification Group (IPOMCG) acknowledged
this complexity and introduced a consensus-based defi-
nition of TRM: death occurring in the absence of pro-
gressive cancer [5,6]. In addition, cause-of-death
attribution system was introduced, validated and sub-
sequently used in two Canadian studies focussing on
differences between TRM and PD death and univariable
risk factors for TRM [7e9].
In this study, we aimed to examine causes of death in
a Dutch cohort of children with cancer, in five-year
follow-up as well as in the first three months after
diagnosis. We also aimed to explore known and novel
risk factors for TRM in a multivariable manner and
describe specific causes of TRM.2. Methods
All children (aged <18 years at diagnosis) diagnosed with
cancer between January 1st 2003 and December 31st
2012, and primarily treated at the University Medical
Center Groningen (UMCG) and the Academic Medical
Center (AMC) Amsterdam were eligible for inclusion.
2.1. Causes of death
TRM was defined in accordance with the aforemen-
tioned IPOMCG definition: death occurring in the
absence of progressive cancer [6]. For all deceased pa-
tients, using the IPOMCG system, we attributed TRM
or PD death and a probable or possible cause of TRM.
In addition, we assigned the relevant ICD-10 (Interna-
tional Statistical Classification of Diseases) codes for
cause of death [10].
2.2. Risk factors
Several factors, such as sex, diagnosis, age at diagnosis,
nutritional status at diagnosis (using [BMI] z-scores, with
“The Netherlands 2010, BMI for age” serving as refer-
ence), Intensity of Treatment Rating Scale 3.0 (ITR 3.0;
reliable and valid classification to determine treatment
intensity of paediatric oncology treatment protocols),
haematopoietic stem cell transplantation (HSCT)
including type, relapse, treatment era, were evaluated to
determine their potential association with TRM and
finally to investigate potential influence of delay and
travel time to the nearest shared care hospital (UMCG
only; using Google Maps with traffic deactivated) [11].
2.3. Data collection
Local data managers provided lists with eligible patients
and relevant outcomes from the local childhood cancer
registries. The individual electronic patient records were
hand searched for missing and additional data (e.g.
length and weight at diagnosis). In March 2018, for all
patients, the survival status was verified in the Dutch
population register to check correctness of our critical
outcome (survival status).
Data regarding cause of death was extracted from the
electronic patient records using a data extraction form
E.A.H. Loeffen et al. / European Journal of Cancer 121 (2019) 113e122 115that underwent a two-phase pilot. The first pilot focused
on usability and consistency and included 20 randomly
selected patients for which two researchers (J.B. and
E.A.H.L.) independently extracted data. Inter-rater
reliability (IRR) had to be >90%, or the pilot was
repeated. The second pilot served to evaluate if the
extracted data were sufficient to unambiguously deter-
mine TRM or PD death and main cause of TRM. In
each centre, 20 patients were randomly selected and the
data extraction form was completed by one researcher
(J.B.), and subsequently two independent raters (J.B.,
R.R.G.K./E.A.H.L.) designated the cause of death
using this form. The form was finalised when the IRR
for cause of death was 95%.
Further data extraction was performed by one
researcher (J.B.).After data extractionwas completed, two
independent researchers (R.R.G.K. and E.A.H.L.) classi-
fied the cause of death of all patients based on the infor-
mation in the data extraction form. These results were
compared, and all discrepancies were discussed in detail
and resolved by consensus (or a third reviewer, W.J.E.T.).
2.4. Statistical analysis
Survival was defined as time from diagnosis till death;
patients who were still alive five years after diagnosis wereTable 1
Patient characteristics.





Age at diagnosis (years), median
(interquartile range)
7.1 (3.1e12.6) 7.7 (3.7e13.0)
Age at diagnosis (categories)
Below 1 year 156 8.8
1e5 years 523 29.6
5e12 years 588 33.3
12e18 years 497 28.2
BMI z-score at diagnosis
Between 2 and 2 1051 84.7
Below 2 96 7.7















BMI, body mass index; HSCT, haematopoietic stem cell transplantation; P
are stated in italics.censored. AsTRMandPDdeath are competing riskss (i.e.
whenonehas occurred, the other cannot occur anymore), a
competing risks analysiswas necessary.TheFine andGray
proportional hazards model was used for these analyses,
yielding subhazard ratios (SHRs) and 95% confidence in-
tervals (CIs) [12]. These analyses were performed uni-
variable andmultivariable; in the latter, only variableswith
a significant association with TRM in univariable analysis
were included. As the ITR 3.0 determination includes
factors such as diagnosis, relapse and HSCT, the ITR 3.0
was separately multivariably analysed without these
aforementioned variables. For categorical variables, the
group inwhich the TRMwas expected to be the lowestwas
chosen as the reference group. Cumulative incidence
functions (CIFs) were plotted to visualise findings.
The significance level of all tests was determined at
p < .05 and tested two-sided. Statistical analyses were
performed using Stata Statistical Software: R15 (Stata-
Corp LLC, College Station, TX, USA) and R v3.5.0 (R
Foundation for Statistical Computing, Vienna,
Austria) [13].
2.5. Sensitivity analysis
In case of missing data concerning cause of death, we




n % n % n %
275 41.7 332 46.3 185 47.7
384 58.3 385 53.7 203 52.3
6.2 (2.0e12.6) 7.5 (3.8e11.8)
28 4.2 103 14.4 25 6.4
205 3.1 213 29.7 105 27.1
225 34.1 199 27.8 164 42.3
201 30.5 202 28.2 94 24.2
488 86.4 422 86.1 141 75.8
36 6.4 36 7.3 24 12.9
41 7.3 32 6.5 21 11.3
84 12.9 137 18.9 113 29.1
569 87.1 586 81.1 275 70.9
101 15.5 4 .6 0 .0
18 2.8 66 9.1 24 6.2
534 81.8 653 90.3 364 93.8
103 15.6 154 21.5 121 31.2
556 84.4 563 78.5 267 68.8
41 6.2 134 18.7 111 28.6
58 8.8 15 2.1 8 2.1
4 .6 5 .7 2 .5
D, progressive disease; TRM, treatment-related mortality. Percentages
E.A.H. Loeffen et al. / European Journal of Cancer 121 (2019) 113e122116This comprised re-running all analyses twice, first with
the cases with an unknown cause of death assigned as
TRM and second with these cases assigned as PD death.
Results were compared with the original findings. If other
variables had missing data, we ran the analyses again
with the missing data imputed using multiple imputation
(number of imputations dependent upon percentage of
missing data according to Graham et al. with the lowest
threshold [<1%] for tolerated power falloff) [14].
2.6. Ethical approval
This study was approved by the Medical Ethical Com-
mittee of the UMCG. Seeking informed consent was




A total of 1764 children diagnosed with cancer were
included, with the median age of 7.1 years (interquartile
range: 3.1e12.6 years). In total, 378 children (21.4%)
died within five years of diagnosis, with a median sur-
vival of 364 days (interquartile range: 171e642 days).
All patient characteristics are shown in Table 1.Fig. 1. Five-year survival status curves, displaying occurrence of treatm
(PD) within all diagnoses combined, children with a hematological m
tumour.3.2. Causes of death
For both phases of the extraction pilot, one round was
sufficient to reach the IRR cut-off (see Supplemental
Material S1 for final data extraction form). Three in
every four deaths were due to PD (n Z 286, 75.7%).
TRM was the cause of death in 81 children (21.4%),
corresponding to a 5-year cumulative incidence of TRM
of 4.59% (95% CI: 3.62%e5.57%). In 11 children (2.9%),
cause of death was either unknown (n Z 10, no infor-
mation in patient record) or not classifiable (n Z 1,
cause fit neither category).
Within diagnosis groups, the distribution of causes of
deaths differed (Fig. 1). In children with a haemato-
logical malignancy, TRM was the major cause of death,
with 58 of 103 deaths (56.3%) due to TRM and 41
(39.8%) due to PD. This was apparent particularly in
children diagnosed with lymphoid leukaemia (nZ 329),
as 29 children (8.8%) died of TRM and 13 died of PD
(4.0%). See also Supplementary Material S2.
Infection accounted for half of TRM (n Z 43,
53.1%). A large proportion of TRM occurred in the first
three months after initial diagnosis (n Z 32, 39.5% of
TRM), of which nearly half (nZ 15, 46.9%) was due to
infection. In fact, a subgroup analysis including only
patients who did not relapse and did not receive an
HSCT showed that nearly two of three (65.2%) deathsent-related mortality (TRM) and death due to progressive disease
alignancy, children with a solid tumour and children with a brain
E.A.H. Loeffen et al. / European Journal of Cancer 121 (2019) 113e122 117due to infection occurred in the first three months after
initial diagnosis. The vast majority (n Z 13, 86.7%) of
these early infection deaths occurred in children with a
haematological malignancy (Table 2), with the associ-
ated pathogen being bacteria in six cases and Candida or
Aspergillus in seven cases. See Supplementary Material
S3 for ICD-10 codes.
3.3. Competitive risk analysis
In univariable competitive risk analyses, variables
significantly associated with occurrence of TRM were
diagnosis, age at diagnosis, ITR 3.0 and HSCT status
(Table 3; for CIFs, see Fig. 2). In a subsequent multi-
variable analysis including these variables but the ITR
3.0, the following factors remained significantly associ-
ated with TRM: diagnosis of haematological malig-
nancy (SHR: 4.29, 95% CI: 2.35e7.85, p < .001), age at
diagnosis <1 year (SHR: 4.30, 95% CI: 2.09e8.87,
p < .001) and use of allogeneic HSCT (SHR: 2.58, 95%
CI: 1.51e4.43, p Z .001). See Fig. 3 for a graphical
representation of the analysis.
Looking at these groups in more detail
(Supplementary Material S3), in patients with anTable 2
Causes of treatment-related mortality, attributed according to the classific
Cause of TRM Total (n Z 1764) Haem
(n Z
n % n
Total number of TRM cases
During complete follow-up 81 100 58
In first 3 months 32 39.5 22
Infection
During complete follow-up 43 53.1 30
In first 3 months 15 18.5 13
Haemorrhage
During complete follow-up 6 7.4 5
In first 3 months 4 4.9 3
Cardiac system
During complete follow-up 3 3.7 2
In first 3 months 0 0.0 0
Immunomediated
During complete follow-up 8 11.1 8
In first 3 months 0 0.0 0
CNS-related
During complete follow-up 15 17.3 6
In first 3 months 9 11.1 4
Respiratory system
During complete follow-up 5 9.9 4
In first 3 months 2 2.5 1
Gastrointestinal system
During complete follow-up 1 1.2 1
In first 3 months 0 0.0 0
External causes
During complete follow-up 2 2.5 0
In first 3 months 0 0.0 0
Classification not possible
During complete follow-up 3 3.7 2
In first 3 months 2 2.5 1
Numbers are presented for the complete follow-up period (first five years a
TRM, treatment-related mortality; CNS, central nervous system. Percentaallogeneic HSCT (nZ 109), the majority of TRM cases
(n Z 19) died due to immunomediated causes (n Z 8,
42.1%) or infection (n Z 7, 36.8%). In patients younger
than one year, TRM rates were especially high in those
diagnosed with leukaemia (n Z 24), with five cases of
TRM (20.8%, two infection, one haemorrhage, one
immunomediated, one central nervous systemerelated)
and one case of PD death (4.2%).
In a separate extra multivariable analysis including
the ITR 3.0 and age at diagnosis, the following factors
were significantly associated with TRM: ITR 3.0 e level
4 (SHR: 2.13, 95% CI: 1.28e3.53, pZ .004), ITR 3.0 e
no treatment received (SHR: 3.20, 95% CI: 1.29e8.51,
pZ .020), age at diagnosis <1 year (SHR: 2.80, 95% CI:
1.38e5.69, p Z .004) and age at diagnosis 12e18 years
(SHR: 1.83, 95% CI: 1.01e3.30, p Z .046).
3.4. Sensitivity analysis
Overall, there were very little missing data. Cause of
death was, as stated, unknown in ten cases (2.6% of all
deaths). As anticipated, the portion of missing data for
BMI z-score at diagnosis (n Z 523, 29.6%) was rela-
tively high. Therefore, multiple imputations wasation system by Alexander et al. [6].
atological
659)
Solid (n Z 717) Brain (n Z 388)
% n % n %
100 15 100 8 100
37.9 6 40.0 4 50.0
51.7 6 40.0 2 25.0
22.4 1 6.7 1 12.5
8.6 1 6.7 0 0.0
5.2 1 6.7 0 0.0
3.4 1 6.7 0 0.0
0.0 0 0.0 0 0.0
13.8 0 0.0 0 0.0
0.0 0 0.0 0 0.0
10.3 3 20.0 6 75.0
6.9 2 13.3 3 37.5
6.9 1 6.7 0 0.0
1.7 1 6.7 0 0.0
1.7 0 0.0 0 0.0
0.0 0 0.0 0 0.0
0.0 2 13.3 0 0.0
0.0 0 0.0 0 0.0
3.4 1 6.7 0 0.0
1.7 1 6.7 0 0.0
fter initial diagnosis) and for the first 3 months after initial diagnosis.
ges are stated in italics.
Table 3
Results of univariable and multivariable competing risks regression analyses (Fine and Gray proportional subhazards model).
Univariable Survival status (5 years after initial diagnosis)
Alive (nZ 1386) TRM (n Z
81)a
PD (n Z 286)a SHRc 95% CIc pc
n % n % n %
Sex
Female 634 80.3 39 4.9 117 14.8 1
Male 752 78.1 42 4.4 169 17.5 0.88 0.57e1.35 0.547
Diagnosis
Solid tumour 563 79.1 15 2.1 134 18.8 1
Haematological tumour 556 84.9 58 8.9 41 6.3 4.33 2.45e7.64 <.001
Brain tumour 267 69.2 8 2.1 111 28.8 0.99 0.42e2.33 0.976
Age at diagnosis
< 1 yrs 116 74.4 13 8.3 27 17.3 2.83 1.38e5.79 .004
1e5 yrs 412 79.4 22 4.2 85 16.4 1.39 0.75e2.59 0.301
5e12 yrs 473 80.7 18 3.1 95 16.2 1
12e18 yrs 385 78.3 28 5.7 79 16.1 1.86 1.03e3.37 .039
Intensity of Treatment Rating 3
Level 1 & 2b 745 92.4 33 4.1 28 3.5 1
Level 3 366 80.6 15 3.3 73 16.1 0.96 0.51e1.80 0.895
Level 4 245 54.6 33 7.3 171 38.1 2.10 1.27e3.48 .004
No treatment received 30 68.2 5 11.4 9 20.5 3.60 1.34e9.67 .011
HSCT
No 1267 81.7 58 3.7 219 14.1 1
Yes, allogeneic 65 61.9 19 18.1 18 17.1 4.93 2.99e8.14 <.001
Yes, autologous 54 50.0 4 3.7 49 45.4 0.99 0.36e2.72 0.978
Relapse
No 1253 87.6 61 4.3 110 7.7 1
Yes 133 39.8 20 6.0 176 52.7 1.39 0.84e2.28 0.200
BMI z-score at diagnosis
2.0 to 2.0 875 62.8 41 2.9 478 34.3 1
< 2.0 63 64.3 5 5.1 30 30.6 1.37 0.54e3.47 0.501
> 2.0 35 81.4 3 7.0 5 11.6 1.92 0.59e6.28 0.279
Treatment era
Jan 2003eDec 2007 652 79.9 42 5.1 122 15.0 1
Jan 2008eDec 2012 734 78.3 39 4.2 164 17.5 0.81 0.52e1.25 0.335
Travel time shared care hospital
<15 min 139 69.2 18 9.0 44 21.9 1
15 min 455 80.8 27 4.8 81 14.4 0.67 0.37e1.22 0.186
Multivariable model 1 n % n % n % SHRd 95% CId pd
Diagnosis
Solid tumour 563 79.1 15 2.1 134 18.8 1
Haematological tumour 556 84.9 58 8.9 41 6.3 4.29 2.35e7.85 <.001
Brain tumour 267 69.2 8 2.1 111 28.8 1.20 0.50e2.88 0.68
Age at diagnosis
< 1 yrs 116 74.4 13 8.3 27 17.3 4.30 2.09e8.87 <.001
1e5 yrs 412 79.4 22 4.2 85 16.4 1.47 0.79e2.74 0.228
5e12 yrs 473 80.7 18 3.1 95 16.2 1
12e18 yrs 385 78.3 28 5.7 79 16.1 1.80 1.00e3.22 0.049
HSCT
No 1267 81.7 58 3.7 219 14.1 1
Yes, allogeneic 65 61.9 19 18.1 18 17.1 2.58 1.51e4.43 .001
Yes, autologous 54 50.0 4 3.7 49 45.4 1.39 0.51e3.80 0.523
Multivariable model 2 n % n % n % SHRd 95% CId pd
Intensity of Treatment Rating 3
Level 1 & 2b 745 92.4 33 4.1 28 3.5 1
Level 3 366 80.6 15 3.3 73 16.1 0.95 0.51e1.79 0.883
Level 4 245 54.6 33 7.3 171 38.1 2.13 1.28e3.53 .004
No treatment received 30 68.2 5 11.4 9 20.5 3.20 1.29e8.51 .020
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Age at diagnosis
< 1 yrs 116 74.4 13 8.3 27 17.3 2.80 1.38e5.69 .004
1e5 yrs 412 79.4 22 4.2 85 16.4 1.39 0.75e2.59 0.294
5e12 yrs 473 80.7 18 3.1 95 16.2 1
12e18 yrs 385 78.3 28 5.7 79 16.1 1.83 1.01e3.30 .046
a 11 patients who died were either classified as unknown (n Z 10) or not classifiable (n Z 1).
b Level 1 and level 2 combined for statistical purposes (too few events in level 1 alone).
c Univariable competing riskss regression analyses (Fine and Gray proportional subhazards model).
d Multivariable competing risks regression analyses (Fine and Gray proportional subhazards model) including diagnosis, age at diagnosis and
HSCT.
TRM, treatment-related mortality; PD, progressive disease; HSCT, haematopoietic stem cell transplantation. Significant p-values are stated in
italics.
E.A.H. Loeffen et al. / European Journal of Cancer 121 (2019) 113e122 119performed using 20 imputations [14]. In all sensitivity
analyses (two-sided extreme scenario testing and
imputed data analysis), the same factors as in the orig-
inal analyses were significantly associated with occur-
rence of TRM.4. Discussion
This is the first study to combine the validated
IPOMCG definition for TRM with a multivariable
competing risks model to explore risk factors for TRM
in a heterogeneous childhood cancer population. In our
cohort of 1764 children with cancer, overall five-year
survival was 78.6%. Over one in five deaths (21.4%) were
treatment-related, and thus, one in every 22 childrenFig. 2. Cumulative incidence functions (CIF) of treatment-related
mortality in the presence of competing riskss (death due to pro-
gressive disease) stratified by (a) type of malignancy and (b) age at
diagnosis.treated for cancer died due to their treatment within 5
years of diagnosis.
In the present study, TRM accounted for the ma-
jority of deaths (56.3%) in children with a haemato-
logical malignancy. Being diagnosed with a
haematological malignancy was one of the factors
related to TRM in multivariable competing
risks model, as well as age at diagnosis <1 year and
receipt of allogeneic HSCT. Hypothesising on these
associations, in haematological malignancies, it might
be the often used combination of glucocorticoids (in-
hibits immune responses) and aggressive chemotherapy
(can cause severe neutropenia) that make patients
susceptible for infections and thus TRM [15]. In chil-
dren aged <1 year, we found that especially those
diagnosed with leukaemia were susceptible for TRM,
which might be explained by the poorer prognosis and
thus more aggressive treatment regimen these children
have to undergo than older children [16]. For children
who had received an allogeneic HSCT, the higher rates
of TRM are likely explained by potentially severe
direct consequences of either the transplant (i.e. graft-
versus-host disease) or the intensive conditioning
regimen (i.e. veno-occlusive disease).
Because our cohort consisted of patients from two of
seven Dutch paediatric oncology hospitals, we
compared the distribution of diagnoses of our cohort
with that of the Dutch Childhood Oncology Group
registry (nationwide, diagnosed between 2003 and
2012) [17]. Our cohort was relatively comparable, with
an overrepresentation of solid malignancies (40.5% vs.
37.4%) and an underrepresentation of haematological
malignancies (37.1% vs. 40.8%) (Supplementary
Material S2). This difference in distribution might
have contributed to the overall survival being slightly
lower than in other cohorts from other high-income
settings [1]. However, with the high rates of TRM in
children diagnosed with a haematological malignancy
and the underrepresentation of this diagnostic group in
our cohort, this implicates that the overall rate of TRM
in the Dutch childhood cancer population might even be
higher than in our cohort.
Comparing our findings with other reports on child-
hood cancer, TRM is challenging because of the
different definitions that are used for TRM.
Fig. 3. Risk table depicting the Fine & Gray subdistribution hazards model. A single silhouette depicts 10 children. In a competitive risk
analysis, people who have suffered the competing event (in this case, PD) remain in the risk set (white silhouettes). Black silhouettes depict
children still alive, blue silhouettes depict children who have died due to TRM and yellow silhouettes depict children who have died due to
PD. TRM, treatment-related mortality; PD, progressive disease.
E.A.H. Loeffen et al. / European Journal of Cancer 121 (2019) 113e122120Nevertheless, one study that focused specifically on
infection-related mortality in children with ALL found
this to be the predominant cause of TRM, as did we [3].
One other study also used the IPOMCG definition
and explored risk factors for TRM in a Canadian het-
erogeneous childhood cancer population and found a
similar 5-year cumulative incidence of TRM (3.9% vs.
4.6% in our study) [9]. Although that study provided
important insights, multivariable analyses were lacking.
Identified univariable risk factors for TRM were leu-
kemia/lymphoma diagnosis, age <1 year, metastatic
disease, diagnosis before 01-01-2008 (data collection
also from 2003 to 2012), HSCT and relapse. Impor-
tantly, survival status in this study was checked for on
31-12-2012; thus, some patients would still be in treat-
ment. In our study, we collected data after 31-12-2017,
so all patients had a complete follow-up of at least five
years. This difference might explain the contrasting
findings with respect to the significance of ‘diagnosis
before 01-01-2008’.
During this study, we identified an important limi-
tation of the classification system as proposed by the
IPOMCG. In this classification, cause of death is
designated as PD or TRM. Although TRM has the
word ‘treatment’ in it, children who die before cancer
therapy initiation are also classified as TRM. This is
more logical than it might seem, as TRM entails deaths
that could be prevented by better supportive care, which
might be the case in children who die before start of
therapy due to, for example, infection or bleeding.
However, children who die due to accidents or homicide
(none in our cohort) are also classified as TRM, which
we believe is questionable. In addition, there are chil-
dren who die due to a medical condition unrelated to
their cancer (e.g. hereditary kidney disease) and thus donot fit any of the categories. Finally, there might be
children for whom it is known that they are deceased
(from e.g. the population register), but for whom the
cause of death is unknown. For the aforementioned
cases, the addition of an ‘unknown/unclassifiable’ cate-
gory would be valuable. Although probably rare, deaths
classified as ‘unknown/unclassifiable’ could either be
treated as an added competitive event in competing
risks analyses or have their influence explored using
two-sided extreme scenario testing, as done in this study.
More, preferably even larger and international,
studies to evaluate causes of death and risk factors for
TRM in children with cancer are needed. In these
studies, data should be collected in a prospective,
standardised (and ideally automated) manner using the
electronic patient records, as this would both increase
completeness and accuracy and decrease workload. In
addition, it would be worthwhile to collect more detailed
information about treatment and supportive care
received, for example, prophylaxis for infections.
This study also has implications for clinical care,
most notably the focus on early infectious complications
in children with haematological malignancies. These
findings, and the notion that with increasing cure rates,
the portion of children that die due to TRM might
continue to grow, further emphasise the importance of
seeking the right balance between desirable and unde-
sirable consequences of treatment.
5. Conclusion
With a complete follow-up for our critical outcome
(survival status), the use of a clear definition of TRM, the
detailed description of designated causes of death for
TRM and the use of multivariable competing riskss
E.A.H. Loeffen et al. / European Journal of Cancer 121 (2019) 113e122 121analyses, this study provides a new insight into the
occurrence and aetiology of TRM. Overall, TRM
accounted for one in five deaths in the first five years after
diagnosis, with 40% of TRM deaths occurring in the first
three months after diagnosis. In children with a haema-
tological malignancy, more children died due to TRM
than due to PD. Infection was the major cause of TRM,
both overall and in the first three months after diagnosis.
Clinical and research effort should be focused on
lowering TRM rates by improving supportive care and
lowering treatment intensity without compromising
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